



TB Program Implementation

Progress

(January to September 2024)

Contents

- 1. TB epidemic in Lao PDR
- 2. End TB strategy
- 3. TB program achievements in 2023
- 4. HANSA2 PBC 7: Reach the unreached to End TB
- 5. TB program implementation progress from January to September 2024
- 6. NTP challenges and next steps

1. TB epidemic in Lao PDR

Estimates of TB burden, 2023

Method for the estimation of incidence (2023): Extrapolated from pre-2020 trends as published in 2020 for countries with no shortfall in notifications compared with 2019

```
Total TB incidence (Number) = 10 000 (6 200-15 000)

Total TB incidence (Rate per 100 000 population) = 132 (81-197)

HIV-positive TB incidence (Number) = 470 (280-710)

HIV-positive TB incidence (Rate per 100 000 population) = 6 (4-9)

MDR/RR-TB incidence (Number) = 63 (31-95)

MDR/RR-TB incidence (Rate per 100 000 population) = 1 (0-1)
```

Method for the estimation of mortality (2023): see section "4.3 Estimating TB mortality among HIV-negative people from estimates of case fatality rates and TB incidence" in the technical appendix.


```
HIV-negative TB mortality (Number) = 680 (340-1 100)

HIV-negative TB mortality (Rate per 100 000 population) = 9 (5-15)

HIV-positive TB mortality (Number) = 76 (44-120)

HIV-positive TB mortality (Rate per 100 000 population) = 1 (1-2)
```

Source: WHO Lao PDR draft country profile 2024



2. END TB Strategy



The End TB Strategy: Vision, Targets and Pillars



Vision:

A world free of TB

Zero TB deaths, Zero TB disease, and Zero TB suffering

Goal:

End the Global TB epidemic

PILLAR 1 Integrated, patient- centered TB care and		Bold policies and supportive systems		PILLAR 3 Intensified research and innovation
prevention	XXX.		XXX.	
Government st	ewardship and	accountability, w	ith monitoring	and evaluation
Buildin	g a strong coa	lition with civil so	ciety and comm	nunities
42 30	cting and pron	noting human righ	ts, ethics and	equity

	MILES	TONES	SDG*	END TB
	2020	2025	2030	2035
Reduction in number of TB deaths compared with 2015 (%)	35%	75%	90%	95%
Reduction in TB incidence rate compared with 2015 (%)	20%	50%	80%	90%
TB-affected families facing catastrophic cost due to TB (%)	s 0%	0%	0%	0%






TARGETS

3. TB program achievements in 2023

Population # (U.N.)	Year	2020	2021	2022*	2023*
# (WHO estimates) (a) (11,000) (10,582) (10,350) (10,108) Notification rate/100k (new & relapse) (b) 109.8 82.7 114 120 TB treatment coverage (b/a) 74% 58% 84% 90% Presumptive TB tested for diagnostic (new test) # 0.63% 0.48% 0.60% 0.64% Presumptive TB with GeneXpert valid test (89%) (98.2%) (98%) (97%) Notified TB cases new and relapse # 8,013 6,123 8,686 9,124 Bacteriologically confirmed PTB new and (55.7%) (78%) (24%) (24.5%) TB notified from ACF # 2,120 1,159 2,031 2,176 (24.5%) TB in children 0-4 # 18 8 26 36 TB in children 5-14 # 55 43 69 67 TB notified by private sector # 193 21 25 32 TB notified by private sector # 193 21 25 32 TB notified by private sector # 193 21 25 32 TB notified prisons # (non ACF) Treatment success of drug sensitive TB (new and relapse) (6,087/6,770) (7,183/8,112) (6,7327,610) TB patients with HIV test # (6,618 5,221 7,679 7,968 (83%) (84.5%) (87.5%) (87.5%) TB/HIV treatment coverage # 369/610 307/610 349/470 369/470 (78.5%) TB/HIV patients on ARV# (30.369 257/307 254/349 287/369 (78.5%) New PLHIV started TPT (CHAS) 598 (60%) 560 (56%) 613 (61%) 703 (70%) 3q Children under 5 started IPT (estimated 0.4 81.4 14/9 40/44 44/52 37/42 86/11.4 14/9 DR-TB patients untolled # 41/49 40/44 44/52 37/42 86/11.4 14/44 41/44 44/52 37/42 86/11.4 14/44 41/44 44/52 37/42 86/11.4 14/44 41/44 44/52 37/42 86/11.4 13/44 14/44 44/52 37/42 86/11.4 13/44 14/44 44/52 37/42 86/11.4 13/44 14/44 44/52 37/42 86/11.4 13/44 14/44 44/52 37/42 86/11.4 13/44 14/44 44/52 37/42 86/11.4 14/44 44/52 37/42 86/11.4 14/44 44/52 37/42 86/11.4 14/44 44/52 37/42 86/11.4 14/44 44/52 37/42 86/11.4 14/44 44/52 37/42 86/11.4 13/44 14/44 44/52 37/42 86/11.4 13/44 14/44 44/52 37/42 86/11.4 14/44 44/52 37/42 86/11.4 13/44 14/44 44/52 37/42 86/11.4 13/44 14/44 44/52 37/42 86/11.4 13/44 14/44 44/52 37/42 86/11.4 13/44 14/44 44/52 37/42 86/11.4 13/44 14/44 44/52 37/42 86/11.4 13/44 14/44 44/52 37/42 86/11.4 13/44 14/44 44/52 37/42 86/11.4 13/44 14/44 44/52 37/42 86/11.4 14/44 44/52 37/42 86/11.4 14/44 44/52 37/42 8	Population # (U.N.)	7.3 M	7.4M	7.5M	7.6M
Notification rate/100k (new & relapse) (b) 109.8 82.7 114 120	TB incidence rate/100k pop.	149	143	138	132
TB treatment coverage (b/a) 74% 58% 84% 90% Presumptive TB tested for diagnostic (new test) # Population testing rate for TB % 0.63% 0.48% 0.60% 0.64% Presumptive TB with GeneXpert valid test 40,878 34,254 43,866 47,128 (Xpert MTB testing coverage) % (89%) (98.2%) (98.2%) (98%) (97%) Notified TB cases new and relapse # 8,013 6,123 8,686 9,124 Bacteriologically confirmed PTB new and relapse # 4,462 4,001 (65.3%) 5,421 (62.1%) 5,625 (61.7%) TB notified from ACF # 2,120 1,159 2,031 2,176 (61.7%) TB notified from ACF # 18 8 26 36 TB in children 0-4 # 18 8 26 36 TB in children 5-14 # 55 43 69 67 TB notified by community/CSOs # 430 270 412 419 TB notified by private sector # 193 21 25 32 TB notified in prisons # (non ACF) 171 219 Treatment success of drug sensitive TB (new and relapse) (6,087/6,770) (7,183/8,112) (6,732/7,610) TB patients with HIV test # 6,618 5,221 7,679 7,968 (83.5%) (83.5%) (84.5%) (87.5%) (73.5%) (78.5%) TB/HIV treatment coverage # 369/610 307/610 349/470 369/470 (78.5%) TB/HIV patients on ARV# 300/369 257/307 254/349 287/369 (%) TB/HIV started TPT (CHAS) 598 (60%) 560 (56%) 613 (61%) 703 (70%) 3q Children under 5 started IPT (estimated 0.4 81.5%) (11%) (13%) (14%) (14%) DR-TB patients enrolled # 41/49 40/44 44/52 37/42 we enrolled among diagnosed (84%) (90%) (855%) (88%) DR-TB treatment success 30/41 33/40 31/44	# (WHO estimates) (a)	(11,000)	(10,582)	(10,350)	(10,108)
Presumptive TB tested for diagnostic (new test) #	Notification rate/100k (new & relapse) (b)	109.8	82.7	114	120
Population testing rate for TB % 0.63% 0.48% 0.60% 0.64%	TB treatment coverage (b/a)	74%	58%	84%	90%
Presumptive TB with GeneXpert valid test (Xpert MTB testing coverage) % (89%) (98.2%) (98.2%) (98.2%) (97%)		46,006	34,880	44,825	48,393
(Xpert MTB testing coverage) % (89%) (98.2%) (98%) (97%)	Population testing rate for TB %	0.63%	0.48%	0.60%	0.64%
Notified TB cases new and relapse # 8,013		40,878	34,254	43,866	47,128
Bacteriologically confirmed PTB new and relapse # and % (55.7%) (55.7%) TB notified from ACF # (2,120 1,159 2,031 2,176 (%) (27%) (19%) (24%) (24.5%) TB in children 0-4 # 18 8 26 36 TB in children 5-14 # 55 43 69 67 TB notified by community/CSOs # 430 270 412 419 TB notified by private sector # 193 21 25 32 TB notified in prisons # (non ACF) 171 219 Treatment success of drug sensitive TB (new and relapse) (6,087/6,770) (7,183/8,112) (6,732/7,610) TB patients with HIV test # (6,618 5,221 7,679 7,968 (% among all TB cases) (83%) (84.5%) /8,776 /9,095 (87.5%) (87.6%) TB/HIV treatment coverage # (369/610 307/610 349/470 369/470 (% of TB/HIV estimated incidence) (60%) (51%) (74%) (78.5%) TB/HIV patients on ARV# 300/369 257/307 254/349 287/369 (%) New PLHIV started TPT (CHAS) 598 (60%) 560 (56%) 613 (61%) 703 (70%) 3q Children under 5 started IPT (estimated 0.4 (18%) (11%) (13%) (14%) (14%) DR-TB patients enrolled # 41/49 40/44 44/52 37/42 % enrolled among diagnosed (84%) (90%) (85%) (88%) DR-TB treatment success 30/41 33/40 31/44	(Xpert MTB testing coverage) %	(89%)	(98.2%)	(98%)	(97%)
TB notified from ACF # 2,120 1,159 2,031 2,176 (%) (27%) (19%) (24%) (24.5%) (24.5%) (27%) (19%) (24%) (24.5%) (24		8,013	6,123	8,686	9,124
(%) (27%) (19%) (24%) (24.5%) TB in children 0-4 # 18 8 26 36 TB in children 5-14 # 55 43 69 67 TB notified by community/CSOs # 430 270 412 419 TB notified by private sector # 193 21 25 32 TB notified in prisons # (non ACF) 171 219 Treatment success of drug sensitive TB (new and relapse) 88.6% 88.5%* - TB patients with HIV test # 6,618 5,221 7,679 7,968 (% among all TB cases) (83%) (84.5%) /8,776 /9,095 (% among all TB cases) (83%) (84.5%) /8,776 /9,095 TB/HIV treatment coverage # 369/610 307/610 349/470 369/470 (% of TB/HIV patients on ARV# 300/369 257/307 254/349 287/369 (%) (81%) (84%) (73%) (78%) New PLHIV started TPT (CHAS) 598 (60%) 560 (56%) 613 (61%)			4,001 (65.3%)	5,421 (62.1%)	
TB in children 0-4 # 18 8 26 36 TB in children 5-14 # 55 43 69 67 TB notified by community/CSOs # 430 270 412 419 TB notified by private sector # 193 21 25 32 TB notified in prisons # (non ACF) Treatment success of drug sensitive TB (new and relapse) (6,087/6,770) (7,183/8,112) (6,732/7,610) TB patients with HIV test # 6,618 5,221 7,679 7,968 (83%) (84.5%) /8,776 /9,095 (87.5%) (87.6%) TB/HIV treatment coverage # 369/610 307/610 349/470 369/470 (% of TB/HIV estimated incidence) (60%) (51%) (74%) (78.5%) TB/HIV patients on ARV# 300/369 257/307 254/349 287/369 (%) New PLHIV started TPT (CHAS) 598 (60%) 560 (56%) 613 (61%) 703 (70%) 3q Children under 5 started IPT (estimated 0.4 per household of pulmonary MTB+) (18%) (11%) (13%) (14%) DR-TB patients enrolled # 41/49 40/44 44/52 37/42 % enrolled among diagnosed (84%) (90%) (85%) (88%) DR-TB treatment success	TB notified from ACF #	2,120	1,159	2,031	2,176
TB in children 5-14 # 55 43 69 67 TB notified by community/CSOs # 430 270 412 419 TB notified by private sector # 193 21 25 32 TB notified in prisons # (non ACF) 171 219 Treatment success of drug sensitive TB (new and relapse) (6,087/6,770) (7,183/8,112) (6,732/7,610) TB patients with HIV test # 6,618 5,221 7,679 7,968 (83%) (84.5%) /8,776 /9,095 (87.5%) (87.6%) TB/HIV treatment coverage # 369/610 307/610 349/470 369/470 (% of TB/HIV estimated incidence) (60%) (51%) (74%) (78.5%) TB/HIV patients on ARV# 300/369 257/307 254/349 287/369 (%) (81%) (84%) (73%) (78%) New PLHIV started TPT (CHAS) 598 (60%) 560 (56%) 613 (61%) 703 (70%) 3q Children under 5 started IPT (estimated 0.4 per household of pulmonary MTB+) (18%) (11%) (13%) (14%) DR-TB patients enrolled # 41/49 40/44 44/52 37/42 % enrolled among diagnosed (84%) (90%) (85%) (88%) DR-TB treatment success 30/41 33/40 31/44	(%)	(27%)	(19%)	(24%)	(24.5%)
TB notified by community/CSOs # 430 270 412 419 TB notified by private sector # 193 21 25 32 TB notified in prisons # (non ACF) 171 219 Treatment success of drug sensitive TB (new and relapse) 89.9% (6,087/6,770) 88.6% (6,732/7,610) 88.5%* - TB patients with HIV test # (% among all TB cases) 6,618 (83%) 5,221 (84.5%) 7,679 (9,095 (87.5%) 7,968 (87.5%) (87.6%) TB/HIV treatment coverage # (% of TB/HIV estimated incidence) 369/610 (60%) (51%) (74%) (78.5%) 369/470 (78.5%) 369/4	TB in children 0-4 #	18	8	26	36
TB notified by private sector # 193 21 25 32 TB notified in prisons # (non ACF) 171 219 Treatment success of drug sensitive TB (new and relapse) (6,087/6,770) (7,183/8,112) (6,732/7,610) TB patients with HIV test # 6,618 5,221 7,679 7,968 (83%) (84.5%) /8,776 /9,095 (87.5%) (87.6%) TB/HIV treatment coverage # 369/610 307/610 349/470 369/470 (% of TB/HIV estimated incidence) (60%) (51%) (74%) (78.5%) TB/HIV patients on ARV# 300/369 257/307 254/349 287/369 (%) (81%) (84%) (73%) (78%) New PLHIV started TPT (CHAS) 598 (60%) 560 (56%) 613 (61%) 703 (70%) 3q Children under 5 started IPT (estimated 0.4 per household of pulmonary MTB+) (18%) (11%) (13%) (14%) DR-TB patients enrolled # 41/49 40/44 44/52 37/42 % enrolled among diagnosed (84%) (90%) (85%) (88%) DR-TB treatment success 30/41 33/40 31/44	TB in children 5-14 #	55	43	69	67
TB notified in prisons # (non ACF) Treatment success of drug sensitive TB (new and relapse) (6,087/6,770) TB patients with HIV test # (6,618 5,221 7,679 7,968 (83%) (84.5%) /8,776 /9,095 (87.5%) (87.6%) TB/HIV treatment coverage # (83%) (84.5%) (307/610 349/470 369/470 (60%) (51%) (74%) (78.5%) TB/HIV patients on ARV# (80) (81%) (84%) (84%) (73%) (78%) New PLHIV started TPT (CHAS) TB/HIV started IPT (estimated 0.4 per household of pulmonary MTB+) (18%) (11%) (13%) (14%) DR-TB patients enrolled # 41/49 40/44 44/52 37/42 % enrolled among diagnosed (84%) (90%) (85%) (88%) DR-TB treatment success 30/41 33/40 31/44	TB notified by community/CSOs #	430	270	412	419
Treatment success of drug sensitive TB (new and relapse) TB patients with HIV test # (% among all TB cases) (% among all TB	TB notified by private sector #	193	21	25	32
and relapse) (6,087/6,770) (7,183/8,112) (6,732/7,610) TB patients with HIV test # (% among all TB cases) 6,618 5,221 7,679 7,968 (% among all TB cases) (83%) (84.5%) /8,776 /9,095 (87.5%) (87.6%) TB/HIV treatment coverage # (% of TB/HIV estimated incidence) (60%) (51%) (74%) (78.5%) TB/HIV patients on ARV# (%) 300/369 (81%) 257/307 (254/349) 287/369 (78%) (%) (81%) (84%) (73%) (78%) New PLHIV started TPT (CHAS) 598 (60%) 560 (56%) 613 (61%) 703 (70%) 3q Children under 5 started IPT (estimated 0.4 per household of pulmonary MTB+) (18%) (11%) (13%) (14%) DR-TB patients enrolled # yenrolled among diagnosed (84%) (90%) (85%) (88%) DR-TB treatment success 30/41 33/40 31/44				171	219
TB patients with HIV test # (83%)	Treatment success of drug sensitive TB (new	89.9%	88.6%	88.5%*	-
(% among all TB cases) (83%) (84.5%) /8,776 (87.5%) /9,095 (87.6%) TB/HIV treatment coverage # (% of TB/HIV estimated incidence) 369/610 (60%) 307/610 349/470 369/470 (78.5%) 369/470 (74%) (78.5%) TB/HIV patients on ARV# (%) 300/369 (81%) 257/307 254/349 287/369 (78%) 287/369 (78%) New PLHIV started TPT (CHAS) 598 (60%) 560 (56%) 613 (61%) 703 (70%) 3q Children under 5 started IPT (estimated 0.4 per household of pulmonary MTB+) 316/1,781 (15%) 175/1,594 (13%) 286/2,128 (14%) 304/2,173 (14%) DR-TB patients enrolled # yenrolled among diagnosed 41/49 (90%) (85%) (85%) (88%) DR-TB treatment success 30/41 33/40 31/44	• •	(6,087/6,770)	(7,183/8,112)	(6,732/7,610)	
TB/HIV treatment coverage # 369/610 307/610 349/470 369/470 (% of TB/HIV estimated incidence) (60%) (51%) (74%) (78.5%) TB/HIV patients on ARV# 300/369 257/307 254/349 287/369 (%) (81%) (84%) (73%) (78%) New PLHIV started TPT (CHAS) 598 (60%) 560 (56%) 613 (61%) 703 (70%) 3q Children under 5 started IPT (estimated 0.4 per household of pulmonary MTB+) (18%) (11%) (13%) (14%) DR-TB patients enrolled # 41/49 40/44 44/52 37/42 (84%) (90%) (85%) (88%) DR-TB treatment success 30/41 33/40 31/44				,	
(% of TB/HIV estimated incidence) (60%) (51%) (74%) (78.5%) TB/HIV patients on ARV# 300/369 257/307 254/349 287/369 (%) (81%) (84%) (73%) (78%) New PLHIV started TPT (CHAS) 598 (60%) 560 (56%) 613 (61%) 703 (70%) 3q Children under 5 started IPT (estimated 0.4 per household of pulmonary MTB+) 316/1,781 175/1,594 286/2,128 304/2,173 per household of pulmonary MTB+) (18%) (11%) (13%) (14%) DR-TB patients enrolled # 41/49 40/44 44/52 37/42 % enrolled among diagnosed (84%) (90%) (85%) (88%) DR-TB treatment success 30/41 33/40 31/44	(% among all TB cases)	(83%)	(84.5%)		
TB/HIV patients on ARV# (%) 300/369 (81%) 257/307 (84%) 254/349 (73%) 287/369 (78%) New PLHIV started TPT (CHAS) 598 (60%) 560 (56%) 613 (61%) 703 (70%) 3q Children under 5 started IPT (estimated 0.4 per household of pulmonary MTB+) 316/1,781 (18%) 175/1,594 (18%) 286/2,128 (14%) 304/2,173 (14%) DR-TB patients enrolled # we enrolled among diagnosed 41/49 (14%) 40/44 (14%) 44/52 (14%) 37/42 (14%) DR-TB treatment success 30/41 (14%) 33/40 (14%) 31/44	TB/HIV treatment coverage #	369/610	307/610	349/470	369/470
(%) (81%) (84%) (73%) (78%) New PLHIV started TPT (CHAS) 598 (60%) 560 (56%) 613 (61%) 703 (70%) 3q Children under 5 started IPT (estimated 0.4 per household of pulmonary MTB+) 316/1,781 (18%) 175/1,594 (11%) 286/2,128 (14%) 304/2,173 (14%) DR-TB patients enrolled # wend among diagnosed 41/49 (11%) 40/44 (11%) 44/52 (11%) 37/42 (11%) Wenrolled among diagnosed (84%) (90%) (85%) (88%) DR-TB treatment success 30/41 (11%) 33/40 (11%) 31/44	(% of TB/HIV estimated incidence)	(60%)	(51%)	(74%)	(78.5%)
New PLHIV started TPT (CHAS) 598 (60%) 560 (56%) 613 (61%) 703 (70%) 3q Children under 5 started IPT (estimated 0.4 per household of pulmonary MTB+) 316/1,781 (18%) 175/1,594 (11%) 286/2,128 (14%) 304/2,173 (14%) DR-TB patients enrolled # we enrolled among diagnosed 41/49 (14%) 40/44 (14%) 44/52 (14%) 37/42 (14%) DR-TB treatment success 30/41 (14%) 33/40 (14%) 31/44		300/369	257/307	254/349	
Children under 5 started IPT (estimated 0.4 per household of pulmonary MTB+) 316/1,781 (18%) 175/1,594 (286/2,128 (304/2,173 (14%)) 304/2,173 (14%) DR-TB patients enrolled # senrolled among diagnosed 41/49 (84%) (90%) (85%) (88%) 48%) 43/40 (20%) (20%) (20%) (20%) (20%) (20%) 48%) DR-TB treatment success 30/41 (33/40 (31/44)) 31/44 31/44	(%)	(81%)	(84%)	(73%)	(78%)
per household of pulmonary MTB+) (18%) (11%) (13%) (14%) DR-TB patients enrolled # 41/49 40/44 44/52 37/42 % enrolled among diagnosed (84%) (90%) (85%) (88%) DR-TB treatment success 30/41 33/40 31/44	New PLHIV started TPT (CHAS)	598 (60%)	560 (56%)	613 (61%)	703 (70%) 3q
DR-TB patients enrolled # 41/49 40/44 44/52 37/42 % enrolled among diagnosed (84%) (90%) (85%) (88%) DR-TB treatment success 30/41 33/40 31/44		316/1,781	175/1,594	286/2,128	304/2,173
% enrolled among diagnosed (84%) (90%) (85%) (88%) DR-TB treatment success 30/41 33/40 31/44		(18%)	(11%)	(13%)	(14%)
DR-TB treatment success 30/41 33/40 31/44		•	•	•	•
	% enrolled among diagnosed				(88%)
1 = 1 1 (= 1 = 1	DR-TB treatment success	30/41 (73%)	33/40 (82%)	31/44 (70%)	

TB treatment coverage of WHO incidence estimate (new and relapse all forms), 2005-2023 *



^{*}DHIS2 TB tracker data, 2023 preliminary data with estimated TB incidence 132/100k

4. HANSA 2 PBC 7: Reach the unreached to End TB

PBC 7: Increase TB prevention and care coverage and reaching the

unreached to End TB

PBC Condition 1:


Number of notified TB cases of all forms (New and Relapse)

PBC Condition 2:


Number of household contact children under 5-year-old received Tuberculosis

Preventive Treatment

4.1 HANSA 2 PBC 7 Condition 1: Number of notified TB cases of all forms (new and relapse)



4.2 HANSA2 PBC 7 Condition 2 Number of household contact eligible received Tuberculosis Preventive Treatment (TPT)



HANSA2 investment and activities

Detail budget by Module

- 1. TB care and preventionAdditional training and supervision
- 2. Key and vulnerable populations TB/DR-TB
- 3. MDR-TB
- 4. TB/HIV
- 5. Program management
- 6. Collaboration with other providers and sectors

4.3 HANSA 2 GF Input based activities

- Procurement of TB diagnostics (GeneXpert cartridges) and medicines (100% Y1, 80% Y2 and 60% Y3 for first line TB drugs)
- Procurement of health equipment (laboratory equipment and X-ray machines)
- Technical assistance
- Matching funds for Laboratory through NCLE

4.4 Investment and activities by source of funding

	2024			2025		
Co-financing	Budget in USD	Budget in LAK	Received budget	Budget in USD	Budget in LAK	
	\$ 1,005,200.81	20,759,264,000	LAK1,306,830,000	1,201,777.42	28,842,658,164.47	
HANSA*	\$1,024,288.99		\$1,024,288.99	1,000,597.80		

*HAI 2024	NSA budget for	Received budget in USD	Budget in LAK	Expenditure	Balance
	Central level	623,704.53			
1	NTC	523,704.73			
2	CHIAs	50,000	1,105,905,000	563,560,420	542,344,580
3	PEDA	50,000	1,105,905,000	509,550,219	596,399,781
II	Provincial level	400,584.46			

Co-financing requested letter for 2024 and 2025



ສາທາລະນະລັດ ປະຊາທິປະໄຕ ປະຊາຊົນລາວ

ສັນຕິພາບ ເອກະລາດ ປະຊາທິປະໄຕ ເອກະພາບ ວັດທະນະຖາວອນ

ກະຊວງສາທາລະນະສຸກ ກົມແຜນການ ແລະ ການເງິນ

ນະຄອນຫຼວງວຽງຈັນ, ວັນທີ: 🤼 🗓 🗓 2024

ຮຽນ: ທ່ານລັດຖະມົນຕີກະຊວງສາທາລະນະສຸກ ທີ່ເຄົາລົບ ແລະ ນັບຖືຢ່າງສາ.

ເລື່ອງ:ຂໍອະນຸມັດການນຳໃຊ້ງົບປະມານ ພາກ 63 ປີ 2024 ໃຫ້ແຜນງານກັນພະຍາດ ແລະ ຄວບຄຸມພະຍາດ

ຕິດຕໍ່ (ແຜນງານ 02 ອຳຕາມ ການຈັດຕັ້າ ແລະ ນ

ກົມແຜນການ ແລະ ການເງິນ ໄດ້ຄົ້ນຄ້ວາພິຈາລະນາອະນຸມັດໃຫ້ ແຜນງານກັນພະຍາດ ແລະ ຄວບຄຸມພະຍາດຕິດຕໍ່ ບັບເລກທີ 1800/ສຫ, ລິງ: (ແຜນງານ 02) ຈັດຕັ້ງປະຕິບັດໂຄງການ ແລະ ກິດຈະກຳ ທີ່ນຳໃຊ້ງົບປະມານພາກ 63 ปີ 2024 *ລວມມຸນຄ່າທັງໝົດ:*

ອີງຕາມ ແຜນຈັດສັນງົບປະເ ເລກທີ 1024/ກຜງ, ລົງລັນ 38.569.446.381 *ກີບ (ສາມສິບແປດຕື້ຫ້າຮ້ອຍຫົກສິບເກົ້າລ້ານສີ່ແສນສີ່ສິບຫົກພັນສາມຣ້ອຍແປດສິບເອັດກີບ* ອີງຕາມ ໜັງສືສະເໜີຂອງກ໌ *ຖ້ວນ)*, ເຊິ່ງໃນນັ້ນງົບປະມານແຕ່ລະພາກສ່ວນມີຄື:

ສິມທິບລັດຖະບານ ຂອງແຜ 28 ມີຖຸນາ 2024:

ອີາຕາມ ຄຳເຫັນ ແລະ ທິດຂື້

ສນຕ້ານເອດ ແລະ ພຕພ ແມ່ນ 10.868,681,000 ກີບ;

2 9417 649 minnelen may must i min 6 041 501 381 By:

2024

ສູນຄວບຄຸມວັນນະໂລກ ແມ່ນ 20,759,264,000 ກີບ. ວັນເກໂຄງການຕັ້ງກ່າວແມ່ນມີຄວາມ ຈຳເວັນເພື່ອເລັ່ງໃຫ້ເວັນສຸດາເເໜ່າຍຄົວຊີ້ບອກທີ່ສະພາແຫ່ງຊາດຮັບຮອງ, ແຜນ ພັດທະນາສາທາລະນະສຸກປະຈຳປີ 2024 ແລະ ທັນກັບກຳນົດເວລາໃນການຈັດຕັ້ງປະຕິບັດແຜນງົບປະມານແຫ່ງລັດ ປະ ຈຳປີ 2024.

ດັ່ງນັ້ນ, ຈຶ່ງສະເໜີມາຍັງທ່ານພິຈາລະນາອະນຸມັດ ເພື່ອຈັດຕັ້ງປະຕິບັດຕາມທາງຄວນດ້ວຍ.

An in sources me as of a singo Sources of the of a singo sources of the of a singo sources of the of the singo sources of the of th

912 182 82 90

ປອ. ດຣ. ບຸນເສີດ ແກວປະສິດ Dr. Bounserth KEOPRASITH



ສາທາລະນະລັດ ປະຊາທິປະໄຕ ປະຊາຊິນລາວ ສັນຕິພາບ ເອກະລາດ ປະຊາທິປະໄຕ ເອກະພາບ ວັດທະນະຖາວອນ

ນະຄອນຫຼວງວຽງຈັນ, ວັນທີ

ໜັງສືສະເໜີ

ຮຽນ: ທ່ານລັດຖະມົນຕີ ກະຊວງແຜນການ ແລະການລົງທຶນ ທີ່ເຄົາລົບ ແລະ ນັບຖືຢ່າງສຸງ ເລື່ອງ: ຂໍງີບປະມານສົມທົບທຶນໂຄງການຊວຍເຫຼືອ ແລະ ທຶນກຸ້ຢືມຈາກສາກິນ ປະຈຳປີ 2025 - ຈິງຕາມ ແຈ້ງການຂອງກະຊວງແຜນການ ແລະການລົງທຶນ ເລກທີ 1577/ກຜທ.ກຜ3, ລົງທີ 3 ກໍລະກົດ 2024 ວ່າດ້ວຍການກະກຽມສ້າງແຜນພັດທະນາເສດຖະກິດ ແລະ ແຜນການລົງທຶນຂອງລັດ ປະຈຳປີ 2025

- ຈຶ່ງຕາມ ການສັ່ງລວມແຜນປະຈຳປີ 2025 ຈາກກົມກອງອ້ອມຂ້າງກະຊວງ ແລະ ທ້ອງຖິ່ນ;

ກະຊວງສາທາລະນະສຸກ ຂໍຖືເປັນກຽດຮຽນສະເໜີມາຍັງທ່ານລັດຖະມົນຕີ ກະຊວງແຜນການ ແລະ ການລົງທຶນ ເພື່ອຊຶ່ງໃບປະມານໃນການຈັດສັນທຶນສົມທົບລັດຖະບານເຂົ້າໃນບັນດາໂຄາການຊ່ວຍເຫຼືອລຳ ແລະ ທຶນກຸ້ຢືມຕ່າງໆປີ2025. ເຊິ່ງລາຍລະອຽດລາຍການທຶນສົມທົບລັດຖະບານທີ່ຕ້ອງການມີດັ່ງລຸ່ມນີ້:

ສົມທົບທຶນກັບອົງການ Gavi ສັກຢາກັນພະຍາດຂອງສູນແມ່ ແລະ ເດັກ

- និ៍ Vaccine

ມນຄ່າ: 33,000,000,000 ກີບ

- Operational Cost

ມູນຄ່າ: 22,000,000,000 ກີບ

2. ສີມທິບຈັດຊື້ຢາຄຸມກຳເນີດສະໜອງໃຫ້ 18 ແຂວງ (UNFPA)

ມນຄ່າ: 2.600.000.000 ກີບ

3. ສີມທິບກອງທຶນໂລກ

ກະຊວງສາທາລະນະສຸກ

2025

ວຽກງານຕ້ານ ວັນນະໂລກ ມຸນຄ່າ: 23,459,885,240 ກີບ

4. ສີມທິບໂຄງການກໍ່ສ້າງໂຮງໝໍມະໂຫສິດ

- ຄ່າເຊົ່າທີ່ດິນສໍາລັບຕຶກຊ່ຽວຊານຈີນ

- ຄຳຮັກສາຄວາມປອດໄຟ

5. ຄ່າຄຸ້ມຄອງເຄື່ອງນຳເຂົ້າ ແລະຍົກເວັ້ນພາສີ

- ຮໍ້ຖອນສີ່ກີດຂວາງ ພ້ອມຂົນໄປຖິ້ມ

6. ສົມທົບການກໍ່ສ້າງໂຮງໝໍມະຫາວິທະຍາໄລດົງໂພສີ ກັບ ເກົາຫີ - ອິບຮົມຄູອາຈານ,ພະນັກງານພາຍໃນ,ເກົາຫຼິ ແລະປະເທດອ້ອມຂ້າງ

7. ສີມທິບກັບອົງການໃຈກ້າ ການກໍ່ສ້າງໂຮງໝໍແຂວງຈຳປາສັກ

- ສຶກສາຜິນກະທິບສິ່ງແວດລ້ອມ ແລະ ສັງຄົມ

ມູນຄ່າ: 900,000,000 ກີບ ມູນຄ່າ: 2,000,000,000 ກີບ

ລວມທັງໝິດ:

114,762,029,320 ກີບ

300,000,000ກີບ

350.000.000ກີບ

ມຸນຄ່າ: 500,000,000 ກີບ

ມູນຄ່າ: 2,000,000,000 ກີບ

(ມີຕາຕະລາງສັງລວມງິບປະມານ ແລະ ເອກະສານທີ່ກ່ຽວຂ້ອງຄັດຕິດມາພ້ອມນີ້) ດັ່ງນັ້ນ. ຈຶ່ງຮຽນສະເໜີມາຍັງທ່ານຊ່ວຍພິຈາລະນາ ແລະ ອະນຸມັດຕາມທາງຄວນດ້ວຍ.

ລັດຖະມົນຕີ

ປອ.ດຣ. ບຸນແປງ ພູມຸມະໄລສິດ

กอ ขอ กักแต่ง ก็การเขยีย

4.5 Planned Co-financing investment and activities


- Communication material and printing for TB program
- Additional training and supervision
- Additional ACF operational costs for provinces and prisons
- Procurement of TB Medicines (first line TB drugs) and diagnostics (0% in Y1, 20% in Y2 and 40% in Y3)
- Procurement of health equipment (laboratory reagents and consumables and additional digital X-ray machines for ACF teams and high TB burden district hospitals)

Implementation and plan activities in 2024	progress	Funding source
Training province and district TB staff based on National TB manual on quality sample collection and delivery, diagnosis, registration, treatment management, contact investigation, M&E including TB tracker Training on GeneXpert and Lab SOPs for lab technicians	 Completed: 8 provinces (BK, LNT, ODX, PSL, LPB, SYL, KM, SVK) Pending: Central hospitals, ATP, SK, SLV, CPS, BLX, SSB, VTP, VTC, HP, XK Completed: 1 session (SK) Pending: 3 sessions 	
Training HCs, VHVs, prison nurses based on National TB manual on quality sample collection and delivery, diagnosis, registration, treatment management, contact investigation, M&E On site coaching by MDR unit team at district/health center level for ambulatory treatment management;	 The detail budget are done, waiting 	• HANSA 1 Y3
Practical Approach on Lung Health (PAL) Course for Hospital doctors at central province and district levels for TB staff including OPD, IPD; Training of central province and district doctors on management of MDR-TB Training of radiologist and technicians on chest X-ray reading in province and district hospitals and prisons	for approval from MOH before conduct the activity.	

Implementation and plan Activities in 2024	progress	Funding source
Train HIV/AIDS workers on screening of active TB and LTBI at province and district levels (in ART and other POC)		
TB/HIV joint on site visits to selected sites (ARTs, POCs) once a quarter by NTC and CHAS		
Monitoring visits by provincial level to district and health center levels; and supervision by District level to 1000 health centers;	 The detail budget 	
Operational costs for Active case finding (ACF) in prisons, high TB burden districts;	are done, waiting for approval from MOH	• HANSA 1 Y3
TB tracker on site coaching in all 162 TB units (central, provincial and district levels) for DQA;	before conduct the activity.	
TB patients' home visit to screen all HHC including children (5,500 BC TB patients per year) and TPT;		
HCs staff conduct home visits to follow-up TB patients treatment and HHC children and adults receiving TPT by HC staff		
Community based TB interventions conducted by CSOs in selected districts		

5.1 TB program implementation progress from January to September 2024 HANSA 2 PBC 7.1 Number of notified TB cases of all forms (New and Relapse) January to September 2024

Number of notified TB cases of all forms (new and relapse)



5.2 TB program implementation progress from January to September 2024 HANSA 2 PBC7.2 Number of household contact children under 5-year-old received TPT January to September 2024





5.3. TB program activities conducted from January to September 2024

- Development of the three years master plan for 2024-2026, and annual operational plan for 2024
- Signed contracts with CSOs: PEDA and CHIAs
- Completing orders of TB drugs and diagnostic tests procurement with GF direct payment (TB drugs to arrive in country October-December 2024)
- Completed the TB nutrition study "Effect of Nutritional Intervention on TB treatment Outcome and financial burden due to TB: Before and after trial in Lao PDR (TBnuts)"
- Updating National guidelines and testing during training sessions in 8 provinces

5.4. TB program activities conducted from January to September 2024

- Conducting outreach ACF in remote districts and in prisons
- Updating the TB information system (TB tracker module 2) to monitor and report on TPT
- Improving laboratory data management with NRL and NCLE
- Continued MDR management and culture follow-up
- On site training and online coaching on updated TB guidelines and TPT implementation with provinces and districts staffs
- NTC and PTC coaching visits in selected remote districts on DQA for TB tracker

6. Gaps/Challenges/Next steps

Gaps/Challenges

- ➤ HANSA 1 Y3 funding has been released to provinces and districts to conduct PBC 7.1 and PBC 7.2 activities end of July 2024
- NTC activities' require long MOH approval process.

- NTC needs to notify 2710 TB cases (average 903 TB cases per month from Oct to Dec 2024) to reach the PBC 7.1 target of 8725 TB cases
- ➤ PBC 7.2 has achieved only 213 (15%) of the annual target on TPT implementation

Next steps

- Provinces and districts level need to speed up implementation as per their costed action plans
- NTC has requested emergency approval for high impact interventions to reach the PBC7 1 and 2 targets including trainings, supervisions, outreach ACF
- ➤ NTC will speed up implementation of ACF at central and provincial levels as soon as after receiving the funding
- ➤ NTC conducts monitoring of the TB tracker
 TPT data and online coaching of TPT
 implementation with provinces and districts

Thank you